Journal of Clinical Oncology
Articles in this Issue
Immunoembolization in liver-predominant metastatic uveal melanoma: A single-center retrospective analysis.
e21600 Background: Uveal melanoma (UM), the most common intraocular malignancy in the U.S., metastasizes in 50% of patients, frequently to the liver (~90%...
Mortality and morbidity outcomes in patients with inflammatory bowel disease with colon cancer: A nationwide analysis.
e15669 Background: Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic condition characterized by inflamma...
Application of artificial intelligence in the development of patient oriented oncology information.
e13660 Background: *This abstract was prepared with the assistance of artificial intelligence to enhance clarity, organization, and accessibility.*...
GBC-11004: An AI-driven novel kinase target with potential to overcome osimertinib resistance in NSCLC.
8614 Background: Osimertinib resistance poses a significant clinical challenge in the treatment of non-small cell lung cancer (NSCLC), with diverse mechan...
Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitor in intermediate-stage HCC exceeding the up-to-7 criteria: A retrospective cohort study.
e16253 Background: This study aimed to assess the efficacy and safety of combining transarterial chemoembolization (TACE) with lenvatinib and a PD-1 inhib...
IMMUNORARE <sup>5</sup> : A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers—The Anaplastic Thyroid Carcinomas Cohort.
TPS2693 Background: In patients with rare cancers, there is an unmet medical need for investigating innovative therapeutics beyond standard first-line tre...
Comparative effectiveness of cabazitaxel (C) vs. lutetium Lu-177 vipivotide tetraxetan (Lu) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
5076 Background: C and Lu are both life-prolonging therapies for pts with mCRPC after progression on androgen receptor pathway inhibitor (ARPI) and doceta...
Testicular function after immune-checkpoint inhibitors treatment.
e24096 Background: Immune-checkpoint inhibitors (ICIs) have revolutionized cancer treatment, demonstrating durable survival benefits across a wide range o...
Preliminary results of a first-in-human phase 1b (aCCeleR8-001) study of S-531011, a humanized anti-CCR8 monoclonal antibody, in patients with advanced solid tumors.
3076 Background: C-C motif chemokine receptor 8 (CCR8) is selectively upregulated in tumor-infiltrating regulatory T cells (TI-Tregs) in multiple cancers,...
Tyrosine kinase inhibitors in children and adolescents with recurrent/refractory sarcomas.
e22011 Background: Treatment of recurrent/refractory (RR) sarcomas is challenging and outcomes with chemotherapy remain poor. Tyrosine kinases are key sig...
Attention-driven multi-scale analysis for accurate tumor classification in digital pathology.
e13703 Background: The analysis of Whole Slide Images (WSIs) in digital pathology faces significant challenges due to their hierarchical structure and gig...
Cost-effectiveness of immunohistochemistry for mismatch repair testing on endometrial intraepithelial neoplasia for early diagnosis of Lynch syndrome.
e17629 Background: Lynch Syndrome (LS) is an autosomal dominant hereditary cancer syndrome characterized by mismatch repair protein (MMR) deficiency that...
Impact of extent of surgical resection on survival outcomes in patients with IDH-mutant anaplastic astrocytomas and IDH mutant anaplastic oligodendrogliomas: A SEER database study.
e14037 Background: Anaplastic astrocytomas and oligodendrogliomas are high-grade gliomas with unique molecular profiles. Molecular markers, such as IDH mu...
Efficacy and safety of combination therapy of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: A systematic review and meta-analysis.
e15124 Background: Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) accounts for 20–30% of adult ALL cases and is characterized by...
The impact of <i>PTEN</i> deletion, <i>TMPRSS2</i> : <i>ERG</i> fusion, and androgen receptor variant 7 (AR-V7) on resistance to novel hormone therapies (NHTs) in castrate-resistant prostate cancer.
e17036 Background: Despite improved treatment outcomes of prostate cancer (PC) from NHTs, acquired resistance via AR-dependent and/or AR-independent pathw...
Phase I summary of the C406 (CART) efficacy and safety for an HER-2–positive breast cancer population.
1025 Background: C406 is a chimeric antigen receptor (CAR) modified autologous T cell, which is a CART targeting HER-2. Here we present the breast cancer...
Updated results of a phase 2 study: Timdarpacept (IMM01) combined with azacitidine (AZA) as the first-line treatment in adults with chronic myelomonocytic leukemia (CMML).
6577 Background: Timdarpacept is a recombinant signal regulatory protein α (SIRPα) IgG1 fusion protein that exerts anti-tumor activity via blocking “Don’t...
A randomized controlled study of tislelizumab combined with concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer and the predictive value of T lymphocyte subsets for efficacy.
2615 Background: Concurrent chemoradiotherapy (CCRT) has been the standard of care for locally advanced cervical cancer (LACC) for over 20 years. However,...
TIGOS-LS, an open-label, randomized study of BMS-986489 vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer.
TPS8124 Background: Standard treatment for limited-stage small-cell lung cancer (LS-SCLC) has recently changed to add durvalumab consolidation after concu...
Outcomes in bone marrow transplant recipients with and without diabetes: A propensity-matched analysis using TriNetX database.
e18557 Background: Bone Marrow Transplant is a high-risk intervention with clinically significant complications. Diabetes Mellitus is a pervasive conditio...
Impact of inflammatory bowel disease on outcomes of colorectal cancer patients undergoing open resection.
3562 Background: Colorectal cancer(CRC) is, at present, the fourth most common cause of cancer in the United States, with more than 140,000 new cases and...
Efficacy and safety of Gegen Qinlian tablets in attenuating immune-related adverse events in NSCLC patients: A randomized controlled, multicenter, open-label trial in China.
e20592 Background: Immune-related adverse events (irAEs) with high incidence are significant challenges, as they often lead to the interruption or discont...
Which systemic regimen to choose in cisplatin-ineligible patients with concurrent radiation therapy for head and neck cancers: carboplatin/5-flurouracil or carboplatin/paclitaxel?
6090 Background: For locally advanced head and neck cancer, concurrent chemotherapy-radiation therapy (ChemoRT) is mainstay of treatment. Carboplatin and...
Epidemiology, clinical characteristics and outcomes of intracranial metastases (ICM) in human papillomavirus positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC).
e18031 Background: HPV+ OPSCC has better outcomes than HPV negative OPSCC but more distant metastatic potential. ICM in HPV+ OPSCC are rare. Data regardin...
The impact of digital patient monitoring on health outcomes and healthcare resource utilization in patients receiving immunotherapy in clinical practice: Results from an early terminated study.
e13711 Background: Patients with cancer who receive immunotherapy experience symptoms that, if not managed promptly, can negatively impact quality of life...